Company news
LSL Pharma Group Inc news in 2026
LSL Pharma Group Inc's news releases, calls and decks from 2026, newest first.
LSL Pharma Group Inc. to present at the "Planet microcap Toronto 2026"
October 22, 2026
Research capital initiates analyst coverage of LSL Pharma Group
October 21, 2026
LSL Pharma Group announces CFO transition
September 10, 2026
LSL Pharma Group reports record revenues and second quarter 2026 results
August 25, 2026
LSL Pharma Group provides update on Steri-Med Pharma manufacturing operations and grants compensation stock options
July 6, 2026
LSL Pharma Group secures new Steri-Med commercial agreements expected to generate over $4 million in recurring annual revenues and appoints Alain R. Dugal as new evp & COO
May 28, 2026
LSL Pharma Group reports record revenues and first quarter 2026 results
May 25, 2026
LSL Pharma Group reports its fourth quarter and year-end 2025 results
April 30, 2026
LSL Pharma Group Inc. announces its participation in the "2026 bloom burton & co. healthcare investor conference"
April 15, 2026
Juno OTC, a wholly-owned subsidiary of LSL Pharma Group, signs binding term sheet with Instapill Private Limited to supply private label Loratadine 10 mg RDT in Canada
April 9, 2026
LSL Pharma Group grants stock options
February 3, 2026
LSL Pharma Group successfully obtained U.S. FDA certification for the manufacturing of ophthalmic ointments for commercialization in the United States
January 28, 2026